Related Experiment Video

Updated: May 10, 2026

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

Characterization of choline kinase in human endothelial cells

Noriko Mori1, Mayur Gadiya, Flonné Wildes

  • 1JHU ICMIC Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University, School of Medicine, Baltimore, MD, USA.

NMR in Biomedicine
|June 19, 2013
PubMed

Insights

High choline kinase-α (Chk-α) is lower in endothelial cells than cancer cells. Downregulating Chk-α inhibits cancer cell proliferation without affecting endothelial cells, supporting its use in cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • High choline kinase-α (Chk-α) expression is common in cancer cells, presenting a therapeutic target.
  • Systemic delivery of Chk-α inhibitors necessitates understanding their effects on endothelial cells in normal and tumor vasculature.
  • Investigating Chk-α expression and functional impact in endothelial cells is crucial for targeted cancer therapies.

Purpose of the Study:

  • To characterize Chk-α expression in human umbilical vein endothelial cells (HUVECs) and breast cancer cells (MDA-MB-231).
  • To evaluate the effect of Chk-α downregulation on HUVECs and MDA-MB-231 cells.
  • To assess the potential of Chk-α as a cancer-specific therapeutic target.

Main Methods:

  • Utilized small interfering RNA (siRNA) to downregulate Chk-α expression in HUVECs and MDA-MB-231 cells.
  • Quantified Chk-α mRNA and protein levels via RT-qPCR and Western blotting.
  • Assessed cell proliferation using standard assays and CD31 immunostaining in tumor xenografts.

Main Results:

  • Basal Chk-α mRNA levels were ~3-fold lower in HUVECs compared to MDA-MB-231 cells.
  • Phosphocholine levels were ~10-fold lower in HUVECs versus MDA-MB-231 cells.
  • Chk-α downregulation significantly reduced proliferation in MDA-MB-231 cells but not in HUVECs; no impact on tumor vasculature (CD31 staining).

Conclusions:

  • Systemic Chk-α downregulation primarily affects cancer cells, sparing endothelial cell proliferation.
  • Chk-α downregulation demonstrates potential as a cancer-specific therapeutic strategy.
  • These findings support the development of Chk-α inhibitors for targeted cancer treatment with minimal vascular side effects.
Keywords:
MRSangiogenesisbreast cancercholine kinaseendothelial cellsphosphocholineproliferation

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Related Concept Videos

Synthesis of Phosphatidylcholine in the ER Membrane01:27

Synthesis of Phosphatidylcholine in the ER Membrane

The ER synthesizes lipids for building cell membranes and performing cellular functions such as energy storage and signaling. The lipid synthesis machinery embedded in the ER membrane primarily collects all reactants from the cytosol. Following synthesis, the secretory pathway and the ER contact sites distribute these lipids to other cellular organelles. Additionally, the energy-rich triacylglycerides are transported from the ER via lipid droplets.
The major components of all eukaryotic cell...
Cholinesterases: Distribution and Function01:22

Cholinesterases: Distribution and Function

Cholinesterases are a group of serine hydrolase enzymes that play a crucial role in the breakdown of choline esters. The two primary types of cholinesterases are acetylcholinesterases (AChEs) and butyrylcholinesterase (BuChEs), which differ in their distribution, function, and substrate specificity. AChEs, also known as true cholinesterases, specifically hydrolyze acetylcholine, while BuChEs, often referred to as pseudocholinesterases, can hydrolyze various choline esters, including...
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...